Navigation Links
VaxGen Issues Rebuttal to MedCap Letter
Date:3/25/2008

y new institutional investors who would

otherwise be attracted by Raven's technology.

VaxGen would note that, in arriving at the terms offered to Raven

stockholders in the proposed merger, it, together with its advisors

at Lazard, used a number of methodologies to value Raven, all of

which showed the proposed transaction to be fair to VaxGen

stockholders based on VaxGen's stock price at the time. Given the

fall in VaxGen's stock price since then, the valuation placed on

Raven's assets is even less demanding, especially in light of recent

transactions in the oncology monoclonal antibody (MAb) arena.

3. ISS' finding that the transaction lacks strategic rationale is, in

the company's view, flawed. It appears to be based on the limited

perspective that VaxGen is a vaccine company whereas Raven is an

antibody company. In fact, most of VaxGen's vaccine programs were

based on recombinant proteins of which monoclonal antibodies are a

subset. As evidence of this, it is noteworthy that VaxGen was the

technology partner and largest founding shareholder of Celltrion,

one of the largest independent manufacturers of mammalian cell

recombinant proteins, including monoclonal antibodies. Further, as

previously disclosed, a number of VaxGen scientists are already

engaged on Raven programs under arms-length contractual

arrangements, suggesting that synergies between the two merged

companies indeed do exist. In reality, VaxGen's later-stage drug

development expertise is highly complementary to Raven's discovery

and early stage capabilities.

4. ISS' has estimated that liquidation of VaxGen would result in

proceeds with a present value of only $0.49 per share. We do not


'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Health care employment grew by 29,000 jobs... show consistent growth during the U.S. recession....n trouble, and health systems are coming closer to... of just administrators. , ...ent continued growing in October despite the shedd...
(Date:11/24/2009)....24/PRNewswire-Asia/--ShanghaiBiolaxyannouncedthe,...provedthe,investigationalnewdrugapplication(IND)fo...nformulationtotreatdiabetes.ThisIND,approvalallows..., Diabetesisadisordercharacteristicofhighbloodglu...ftenresultinseveremicro-and,macro-vasculardiseases...
(Date:11/24/2009)...TL , TORONTO,Nov.24/PRNewswire-FirstCall/-Ham...nc.,aleadingproviderofadvancedlasersystemsandinstr...ets,todayreportedoperationalandfinancialresultsfor...ghlights,-Revenuewas$1.46millioncomparedwith$1.43...mparedwith66.1percentinQ3,2008,-Netlossreducedto$1...
(Date:11/24/2009)...November24/PRNewswire/--HealthRoboticstodayannounc...upofselected,investors.ThisrecentlyformedToronto-b...anada,Inc.andwillmarket,install,andsupport,HealthR...e,revolutionaryproductofferingsi.v.STATION(TM),i.v...alsoprovideassistanceonan"asneeded,basis"toitsstra...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...ARY, Dec. 21 /PRNewswire-FirstCall/ - Oncolytics B...has completed patient enrolment in,its Phase Ia/Ib...al,delivery of REOLYSIN(R) in combination with rad...total of 23 patients received a range of two to,si... dosages up to a,maximum of 1x10(10) TCID(50) with...
...LOTTESVILLE, Va., Dec. 21 Diffusion Pharmaceutica...commercializing,first-in-class drugs utilizing a n...usion, today announced that one of its key advisor...co-inventor of the underlying,technology of Amgen,..., a,erythropoiesis stimulating agent (US Patent No...
...CETON, N.J., Dec. 21 Otsuka Pharmaceutical,Develo...at the U.S. Food,and Drug Administration has accep... investigational oral once-daily medication tolvap...t, for two indications: treatment of,adults with w...ia.(1) These,indications are based on data from th...
Other Biology Technology:Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial 2Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics 2New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration 2New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration 3
(Date:11/24/2009)... 24, 2009) -- The Wildlife Conservation Society (W...st remaining population of Siberian tigers has lik...of poaching and habitat loss. , WCS ... of what needs to be done to protect remaining pop... The report was released by the Siberian Tiger ...
(Date:11/24/2009)...atter of debate. A high-profile study a few years ...heir carbon from trees and leaves, evidence for a ...c ecosystems. , But new research from the Univer...true. Algae provide a much richer diet for fish an...hed this week in the Proceedings of the National ...
(Date:11/24/2009)...nish . , The presence of increased body fat,...ances in the blood, hinders the loss and maintenan...of the University of Navarra conducted by Estbaliz...rmacy. , The project, entitled "A nutrigenetic a...f body weight and inflammation," examines how the ...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2Cord Blood America Retires Note in Continuing Effort to Reduce Debt 58743 1Cord Blood America Retires Note in Continuing Effort to Reduce Debt 58743 2BIA Publishes White Paper 3A ISO 9000 Role in Document Review Emphasizes Quality Equals Defensibility 5183 1BIA Publishes White Paper 3A ISO 9000 Role in Document Review Emphasizes Quality Equals Defensibility 5183 2BIA Publishes White Paper 3A ISO 9000 Role in Document Review Emphasizes Quality Equals Defensibility 5183 3GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 1GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 2GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 3GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 4
...ce sheet , Studies have indicated that the Green...easing average summer air temperatures in southern... the ice sheet,s mass from 1958 through 2008, Rign...ch is obtained from remote sensing techniques; and...el of melting ice and snowpack accumulation. The a...
...evier, a leading publisher of scientific, technica...nnounced today that it will publish NJAS - Wageni...er.com/locate/njas ) on behalf of Royal Netherland...g in 2009 with Volume 57, issue 1. , NJAS - Wage...1952, is the quarterly journal of the Royal Nether...
...rthern migration of invasive marine is one of many...pening day presentations at the First World Confer... las Ciencias, in Valencia. , Investigators repor...d at 50 km per decade, a distance far greater than... difference may be due to the rapid dispersion of ...
Other Biology News:AGU journal highlights: Nov. 11, 2008 2AGU journal highlights: Nov. 11, 2008 3AGU journal highlights: Nov. 11, 2008 4AGU journal highlights: Nov. 11, 2008 5AGU journal highlights: Nov. 11, 2008 6AGU journal highlights: Nov. 11, 2008 7AGU journal highlights: Nov. 11, 2008 8AGU journal highlights: Nov. 11, 2008 9AGU journal highlights: Nov. 11, 2008 10Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 2Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 3Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 4
Rabbit Anti-Human Thymosin beta4 Polyclonal Antibody, Unconjugated from Calbiochem
...proven, validated Sanger dideoxy DNA sequencing, t...ughput capillary sequencing instrumentation. The p... both directions. The use of DNA sequencing also p...irming the location of the polymorphic site. Rap...
Mini ReadySub-Cell GT Cell and PowerPac Basic Power Supply from Bio-Rad
...220-240 V, is used for nucleic acid separation usi...em includes the modular Sequi-Gen GT electrophores...ids with single base-pair resolution and includes ...bonded inner glass plate, outer glass plate, and c...
Biology Products: